CD40 and familial pancreatic carcinoma: In addition, the targeting of CD40 with agonistic monoclonal antibodies (mAb) has shown effective results in different cancer types, such as pancreatic cancer, where both the adaptive and innate immune systems drive the main mechanisms of action of the CD40-targeted therapy.22